Drugs / Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)

Follow last change May 2022 re-read 3 minutes ago

Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)

Developed for: human papilloma virus infection
Investigated by: Beijing Health Guard Biotechnology, Inc · Jiangsu Province Centers for Disease Control and Prevention · Nanjing Sangruisi Pharmaceutical Technology Co., Ltd · National Institutes for Food and Drug Control, China · School of Public Health of Southeastern University

today NCT05680454 · Ph 1

2020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT05680454	Sep 2019 → Apr 2020	human papilloma virus infection	Beijing Health Guard Biotechnology, Inc	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05680454 ↗
Modality	Vaccine	“Human Papillomavirus (HPV) Vaccine” NCT05680454 ↗